Impact of Early Versus Late Antiretroviral Treatment Initiation on Naive T Lymphocytes in HIV-1-Infected Children and Adolescents – The-ANRS-EP59-CLEAC Study

Abstract

BackgroundThe early initiation of antiretroviral therapy (ART) in HIV-1-infected infants reduces mortality and prevents early CD4 T-cell loss. However, the impact of early ART on the immune system has not been thoroughly investigated in children over five years of age or adolescents. Here, we describe the levels of naive CD4 and CD8 T lymphocytes (CD4/CD8TN), reflecting the quality of immune reconstitution, as a function of the timing of ART initiation (early (<6 months) versus late (≥24 months of age)).MethodsThe ANRS-EP59-CLEAC study enrolled 27 children (5-12 years of age) and nine adolescents (13-17 years of age) in the early-treatment group, and 19 children (L-Ch) and 21 adolescents (L-Ado) in the late-treatment group. T lymphocytes were analyzed by flow cytometry and plasma markers were analyzed by ELISA. Linear regression analysis was performed with univariate and multivariate models.ResultsAt the time of evaluation, all patients were on ART and had a good immunovirological status: 83% had HIV RNA loads below 50 copies/mL and the median CD4 T-cell count was 856 cells/µL (interquartile range: 685-1236 cells/µL). In children, early ART was associated with higher CD8TN percentages (medians: 48.7% vs. 31.0%, P = 0.001), and a marginally higher CD4TN (61.2% vs. 53.1%, P = 0.33). In adolescents, early ART was associated with low CD4TN percentages and less differentiated memory CD8 T cells. CD4TN and CD8TN levels were inversely related to cellular activation and gut permeability.ConclusionIn children and adolescents, the benefits of early ART for CD8TN were clear after long-term ART. The impact of early ART on CD4TN appears to be modest, because pediatric patients treated late respond to HIV-driven CD4 T-lymphocyte loss by the de novo production of TN cells in the thymus. Our data also suggest that current immune activation and/or gut permeability has a negative impact on TN levels.Clinical Trial RegistrationClinicalTrials.gov, identifier NCT02674867.

Effect of the timing of antiretroviral treatment initiation on CD4 count in children and youths living with HIV in North India

“…Along with increase in CD4 count, early ART intervention is beneficial for CD8 + T-cells which are a crucial element of the immune system and participate actively to combat viral infections. 22 Saluzzo et al 23 reported that once the patient has acquired HIV, CD4 + tissue-resident memory T cells that are present in the skin get depleted and are replenished only upon early ART initiation. Moreover, WHO has recommended in its 2016 guidelines to start ART for every person living with HIV irrespective of his/her clinical or immunological stage.…”

Host Immunity to Mycobacterium tuberculosis Infection Is Similar in Simian Immunodeficiency Virus (SIV)-Infected, Antiretroviral Therapy-Treated and SIV-Naïve Juvenile Macaques

“…Whether later ART initiation would result in a similar host responses and rate of TB progression warrants further investigation. Although, early ART has been noted to have beneficial effects on CD8 T cells in HIV-infected children ( 85 ). Our data indicate that early ART initiation provides not only viral control but may also reduce TB severity and mortality in children living with HIV.…”

Thirteen-year viral suppression and immunologic recovery of LPV/r-based regimens in pediatric HIV treatment: a multicenter cohort study in resource-constrained settings of China

“…A study on Children and Adolescents showed that 8% of children did not recover CD4 count >500 after 2 years of therapy (16). This disparity between adults and children might be attributed to the residual thymus function in children and adolescents (39)(40)(41). Additionally, in HIV-infected children, the immune response is notably influenced by Natural Killer (NK) cells.…”